Camelid VHH affinity ligands enable separation of closely related biopharmaceuticals
详细信息 查看全文
- 作者：Timothy M. Pabst ; Michaela Wendeler ; Xiangyang Wang ; Sandra Bezemer ; Pim Hermans and Alan K. Hunter
- 刊名：Biotechnology Journal
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：12
- 期：2
- 全文大小：466K
- ISSN：1860-7314
文摘
Interest in new and diverse classes of molecules such as recombinant toxins, enzymes, and blood factors continues to grow for use a biotherapeutics. Compared to monoclonal antibodies, these novel drugs typically lack a commercially available affinity chromatography option, which leads to greater process complexity, longer development timelines, and poor platformability. To date, for both monoclonal antibodies and novel molecules, affinity chromatography has been mostly reserved for separation of process-related impurities such as host cell proteins and DNA. Reports of affinity purification of closely related product variants and modified forms are much rarer. In this work we describe custom affinity chromatography development using camelid VHH antibody fragments as "tunable" immunoaffinity ligands for separation of product-related impurities. One example demonstrates high selectivity for a recombinant immunotoxin where no binding was observed for an undesired deamidated species. Also discussed is affinity purification of a coagulation factor through specific recognition of the gamma-carboxylglutamic acid domain.